COMPASS Pathways plc

General Information
Business:

We are a mental health care company pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support, to help people with treatment-resistant depression. We have developed a proprietary high-purity polymorphic crystalline formulation of psilocybin, COMP360. In 2019, we completed a Phase I clinical trial administering COMP360, along with psychological support, to 89 healthy volunteers, the largest randomized, controlled trial with psilocybin therapy to date. In this trial, we observed that COMP360 was generally well-tolerated and supported continued progression of Phase IIb studies. 

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 48
Founded: 2012
Contact Information
Address 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, United Kingdom
Phone Number +1 (646) 905-3974.
Web Address http://www.compasspathways.com
View Prospectus: COMPASS Pathways plc
Financial Information
Market Cap $591.6mil
Revenues $0 mil (last 12 months)
Net Income $-38.8 mil (last 12 months)
IPO Profile
Symbol CMPS
Exchange NASDAQ
Shares (millions): 7.5
Price range $17.00 - $17.00
Est. $ Volume $127.5 mil
Manager / Joint Managers Cowen/ Evercore ISI/ Berenberg
CO-Managers Canaccord Genuity
Expected To Trade: 9/18/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change